Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab

Authors

  • Wulyo Rajabto Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Agnes Stephanie Harahap Department of Anatomical Pathology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Handy Nugraha Putra Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Keywords:

Follicular lymphoma, symptom, chemoimmunotherapy, Bendamustine, Rituximab, lymphoma, hematology

Abstract

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma in Western countries after diffuse large B-cell lymphoma. Most patients with FL present with asymptomatic disease. Survival rates have been rising over time mainly due to advancing therapeutic strategiesA-51-year-old male with a history of well-controlled diabetes mellitus treated with insulin presented to the policlinic of hematology-medical oncology with worsening right inguinal lymphadenopathy for >3 months. He had no complaints of prolonged fever, night sweat, or weight loss. Initial physical examination revealed a healthy male with bulky right inguinal lymphadenopathy. The patient was then referred to a surgeon, and excisional biopsy of the enlarged right inguinal lymph nodes was performed. Therefore, stage II bulky symptomatic low-grade FL was established. We administered chemoimmunotherapy with rituximab and bendamustine every 3 weeks for six cycles. The patient tolerated the treatment well and completed six cycles of chemoimmunotherapy, and the follow-up FDG PET/CT showed complete remission of the disease.The patient achieved complete remission after series of chemoimmunotherapy with Bendamustine–Rituximab. Future assessment is still required for this patient to ensure the remission status of the lymphoma

References

Cho SH, Suh CW, Do YR, et al. Clinical features and survival of patients with follicular lymphoma in Korea. Clin Lymphoma Myeloma Leuk. 2016;16(4):197-202.

Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica. 2022;107(1):7-18.

Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clin Transl Oncol. 2015;17(12):1014-9.

Clauwaert M, Galle V, Maerevoet M, et al. Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma 2019. Belg J Hematol. 2020;11(2):67-74.

Cerhan JR. Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am. 2020;34(4):631-46.

Muto R, Miyoshi H, Sato K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Medicine. 2018;7(11):5843-58.

Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2021;32(3):298-308.

Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicenter, randomized, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-10.

Flinn IW, Van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with Bendamustine plus Rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow up study. J Clin Oncol. 2019;37(12):984-91.

McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Brit J Haematol. 2020;191:363-81.

Zoellner A, Herfarth K, Herold M, et al. Clinical practice guideline: Follicular lymphoma—diagnosis, treatment, and follow-up. Dtsch Arztebl Int. 2021;118: 320-5.

Downloads

Published

2024-07-16

How to Cite

Rajabto, W., Harahap, A. S., & Putra, H. N. (2024). Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab. Acta Medica Indonesiana, 56(2), 249. Retrieved from https://actamedindones.org/index.php/ijim/article/view/2722

Issue

Vol. 56 No. 2 (2024): Acta Medica Indonesiana

Section

MEDICAL ILLUSTRATION

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.